Levosimendan Improves Renal Outcome in Cardiac Surgery: A Randomized Trial

Effects of levosimendan on mortality in patients undergoing cardiac surgery: A systematic review and meta-analysis

“…A total of 15 trials compared levosimendan with placebo, 9 trials compared levosimendan with other inotropes, including epinephrine (1 trial), dobutamine (4 trials), and milrinone (3 trials), 2 other trials compared levosimendan with nitroglycerin or with the intra‐aortic balloon pump. To minimize heterogeneity across the trials, quantitative synthesis was only performed for the 15 placebo‐controlled randomized trials …”

“…Eleven studies reported data on all‐cause mortality and the data were suitable for meta‐analysis (Figure ) . The pooled OR was 0.76 (95% CI: 0.55‐1.04, P = 0.09), indicating no superiority of levosimendan over placebo in terms of mortality.…”

Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis

“…Further filtering led to 60 articles scanned during the abstract review. From the 27 full‐text articles reviewed, 14 studies were finally included for systematic review and meta‐analysis . Figure depicts the flow diagram for the search process.…”

“…From the 27 full-text articles reviewed, 14 studies were finally included for systematic review and meta-analysis. [8][9][10][11][12][13][14][15][16][17][18][19][20][21] Figure 1 depicts the flow diagram for the search process. Tables 1 and 2 present an overview and quality review of the included studies.…”

Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case

“…The clinical benefits of using levosimendan in cardiac surgery have been demonstrated in a number of studies [1,17,[36][37][38][39][40]. In the current economic analysis, which evaluated the costs of levosimendan compared with dobutamine in patients requiring inotropic support following cardiac surgery in Germany, levosimendan was found to be cost saving from the hospital and health insurance perspectives.…”